ABSI Stock Forecast 2025-2026
Distance to ABSI Price Targets
ABSI Price Momentum
10 Quality Stocks Worth Considering Now
Researching Absci (ABSI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ABSI and similar high-potential opportunities.
Latest ABSI Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ABSI has a bullish consensus with a median price target of $9.00 (ranging from $5.00 to $13.00). Currently trading at $3.14, the median forecast implies a 186.6% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from George Farmer at Scotiabank, projecting a 314.0% upside. Conversely, the most conservative target is provided by Scott Schoenhaus at Keybanc, suggesting a 59.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABSI Analyst Ratings
ABSI Price Target Range
Latest ABSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 22, 2025 | Needham | Gil Blum | Buy | Initiates | $9.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Jan 8, 2025 | Keybanc | Overweight | Maintains | $0.00 | |
| Dec 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Dec 3, 2024 | Guggenheim | Vamil Divan | Buy | Reiterates | $10.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Oct 2, 2024 | Guggenheim | Vamil Divan | Buy | Initiates | $10.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $6.00 |
| Jul 3, 2024 | Morgan Stanley | Vikram Purohit | Overweight | Initiates | $7.00 |
| May 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Mar 26, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $9.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Mar 14, 2024 | Scotiabank | George Farmer | Sector Outperform | Initiates | $13.00 |
| Mar 6, 2024 | Truist Securities | Robyn Karnauskas | Buy | Reiterates | $9.00 |
| Mar 4, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $8.00 |
| Jan 8, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $7.00 |
| Jan 5, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
Absci Corporation (ABSI) Competitors
The following stocks are similar to Absci based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Absci Corporation (ABSI) Financial Data
Absci Corporation has a market capitalization of $360.65M with a P/E ratio of -2.6x. The company generates $4.21M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +128.6% quarter-over-quarter, while maintaining an operating margin of -1,698.7% and return on equity of -49.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Absci Corporation (ABSI) Business Model
About Absci Corporation
Biotechnology company specializing in drug discovery.
The company utilizes artificial intelligence and synthetic biology to streamline the discovery and development of therapeutic proteins. By leveraging machine learning alongside its proprietary platform, it aims to enhance the efficiency of drug development processes, thus generating revenue through partnerships and collaborations in the biopharmaceutical sector.
Based in Vancouver, Washington, Absci Corporation is positioned as a key innovator in the healthcare and biotech industries. Its focus on rapid and cost-effective medicine delivery could lead to significant advancements in pharmaceutical design and manufacturing, potentially transforming global healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
155
CEO
Mr. Sean McClain
Country
United States
IPO Year
N/A
Website
www.absci.comAbsci Corporation (ABSI) Latest News & Analysis
Absci Corporation (Nasdaq: ABSI) will release its Q4 and full-year 2024 financial and operating results on March 18, 2025, after market close.
Absci Corporation's upcoming financial report may reveal insights into its performance and growth potential, impacting stock valuation and investor sentiment.
Absci Corporation granted a stock option for 162,800 shares to a new non-executive employee as part of its 2023 Inducement Plan, approved by its Board's Compensation Committee.
Absci's grant of stock options signals confidence in attracting talent, potentially enhancing innovation and growth, which can positively influence stock performance and investor sentiment.
Absci Corporation (Nasdaq: ABSI) will participate in the virtual KeyBanc Capital Markets Healthcare Forum, as announced on March 4, 2025.
Absci Corporation's participation in a major healthcare forum highlights its strategic positioning in the AI drug development space, potentially attracting investor interest and impacting stock performance.
Absci Corporation (Nasdaq: ABSI) will participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA, on February 18, 2025.
Absci Corporation's participation in a major healthcare conference highlights its visibility and potential growth in the AI-driven drug development sector, attracting investor interest.
Absci Corporation (Nasdaq: ABSI) will participate in the Guggenheim Securities SMID Cap Biotech Conference in New York, as announced on January 22, 2025.
Absci Corporation's participation in a prominent biotech conference signals potential visibility, networking opportunities, and investor interest, which could positively impact its stock performance.
Needham has initiated coverage on Absci Corporation (ABSI), focusing on its use of AI and synthetic biology in drug and target discovery to enhance protein therapies.
The initiation of coverage by Needham signals potential growth and interest in Absci Corporation, highlighting its innovative approach which could impact its stock performance and market valuation.
Frequently Asked Questions About ABSI Stock
What is Absci Corporation's (ABSI) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Absci Corporation (ABSI) has a median price target of $9.00. The highest price target is $13.00 and the lowest is $5.00.
Is ABSI stock a good investment in 2025?
According to current analyst ratings, ABSI has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABSI stock?
Wall Street analysts predict ABSI stock could reach $9.00 in the next 12 months. This represents a 186.6% increase from the current price of $3.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Absci Corporation's business model?
The company utilizes artificial intelligence and synthetic biology to streamline the discovery and development of therapeutic proteins. By leveraging machine learning alongside its proprietary platform, it aims to enhance the efficiency of drug development processes, thus generating revenue through partnerships and collaborations in the biopharmaceutical sector.
What is the highest forecasted price for ABSI Absci Corporation?
The highest price target for ABSI is $13.00 from George Farmer at Scotiabank, which represents a 314.0% increase from the current price of $3.14.
What is the lowest forecasted price for ABSI Absci Corporation?
The lowest price target for ABSI is $5.00 from Scott Schoenhaus at Keybanc, which represents a 59.2% increase from the current price of $3.14.
What is the overall ABSI consensus from analysts for Absci Corporation?
The overall analyst consensus for ABSI is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are ABSI stock price projections?
Stock price projections, including those for Absci Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
